Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2

被引:89
作者
Da Costa, X
Kramer, MF
Zhu, J
Brockman, MA
Knipe, DM
机构
[1] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Comm Virol, Boston, MA 02115 USA
关键词
D O I
10.1128/JVI.74.17.7963-7971.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A number of studies have shown that replication-defective mutant strains of herpes simplex virus (HSV) can induce protective immunity in animal systems against wild-type HSV challenge. However, all of those studies used viruses with single mutations. Because multiple, stable mutations provide optimal levels of safety for live vaccines, we felt that additional mutations needed to be engineered into a candidate vaccine strain for HSV-2 and genital herpes. We therefore isolated an HSV-2 strain with deletion mutations in two viral DNA replication protein genes, UL5 and UL29. The resulting double deletion mutant virus strain, dl5-29, fails to form plaques or to give any detectable single cycle yields in normal monkey or human cells. Nevertheless, dl5-29 expresses nearly the same pattern of gene products as the wild-type virus or the single mutant viruses and induces antibody titers in mice that are equivalent to those induced by single deletion mutant viruses. Therefore, it is feasible to isolate a mutant HSV strain with two mutations in essential genes and with an increased level of safety but which is still highly immunogenic.
引用
收藏
页码:7963 / 7971
页数:9
相关论文
共 35 条
[1]   The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells [J].
Aubert, M ;
Blaho, JA .
JOURNAL OF VIROLOGY, 1999, 73 (04) :2803-2813
[2]  
AUGENBRAUN MH, 1994, INFECT DIS CLIN N AM, V8, P439
[3]   Herpes simplex virus vaccines [J].
Bernstein, DI ;
Stanberry, LR .
VACCINE, 1999, 17 (13-14) :1681-1689
[4]   A Genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease [J].
Boursnell, MEG ;
Entwisle, C ;
Blakeley, D ;
Roberts, C ;
Duncan, IA ;
Chisholm, SE ;
Martin, GM ;
Jennings, R ;
Challanain, DN ;
Sobek, I ;
Inglis, SC ;
McLean, CS .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (01) :16-25
[5]  
Brubaker JO, 1996, J IMMUNOL, V157, P1598
[6]   Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - Two randomized controlled trials [J].
Corey, L ;
Langenberg, AGM ;
Ashley, R ;
Sekulovich, RE ;
Izu, AE ;
Douglas, JM ;
Handsfield, HH ;
Warren, T ;
Marr, L ;
Tyring, S ;
DiCarlo, R ;
Adimora, AA ;
Leone, P ;
Dekker, CL ;
Burke, RL ;
Leong, WP ;
Straus, SE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (04) :331-340
[7]  
CURTISS R, 1994, DEV BIOL STAND, V82, P23
[8]   Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection [J].
Da Costa, XJ ;
Jones, CA ;
Knipe, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6994-6998
[9]   Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease [J].
DaCosta, XJ ;
Bourne, N ;
Stanberry, LR ;
Knipe, DM .
VIROLOGY, 1997, 232 (01) :1-12
[10]   The genome sequence of herpes simplex virus type 2 [J].
Dolan, A ;
Jamieson, FE ;
Cunningham, C ;
Barnett, BC ;
McGeoch, DJ .
JOURNAL OF VIROLOGY, 1998, 72 (03) :2010-2021